{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/febrile-seizure/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"0f68597e-aa52-5fe5-a17f-664a2d801310","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 6c6b54c9-1724-4573-b675-bfd4f7c2c48d --><h2>Changes</h2><!-- end field 6c6b54c9-1724-4573-b675-bfd4f7c2c48d -->","summary":null,"htmlStringContent":"<!-- begin item c766f922-fb03-40de-a862-04c65134a61a --><!-- begin field 617d5990-7e84-459b-b605-00f75ba1de36 --><p><strong>October to November 2018 </strong>— reviewed. A literature search was conducted in October 2018 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone minor restructuring, and new nodes on Assessment and Differential diagnosis have been added. Recommendations in the Management section have been updated in line with current literature.</p><!-- end field 617d5990-7e84-459b-b605-00f75ba1de36 --><!-- end item c766f922-fb03-40de-a862-04c65134a61a -->","topic":{"id":"d0a3a70d-e768-56e2-b85b-7a6c0567dce9","topicId":"943c6b53-5fc0-4f14-bd2b-373f5b53aa25","topicName":"Febrile seizure","slug":"febrile-seizure","lastRevised":"Last revised in November 2018","chapters":[{"id":"919cf939-380d-5d7b-8c72-1a9608c65207","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"64f9924b-1ddf-5330-9c46-cc4fbab61666","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"8b31df9d-3e48-548c-9547-2e93ba970361","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0f68597e-aa52-5fe5-a17f-664a2d801310","slug":"changes","fullItemName":"Changes"},{"id":"a0f71bf4-ae35-5e4c-856e-fb68cdc9d501","slug":"update","fullItemName":"Update"}]},{"id":"d6839971-ba18-5ac8-98be-b0f9d596ff75","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d7d6363d-ec4d-581e-a5be-7a457048d32a","slug":"goals","fullItemName":"Goals"},{"id":"9d9dd4fa-b044-5d41-8b4f-7e5588bc5b69","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"9be5ce9c-b886-511e-95af-38f9158bf35f","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c89fe1ec-9095-5d7a-8b01-bf7f2d3416f3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"78e1df68-d68b-54af-8828-e824a1ebb435","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"86e850e3-8b4c-5938-9619-23063f64c9f2","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"fb462f25-b012-50cc-9294-1e6cfa65420f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7080b1c9-dfd6-5c34-b009-b598e8db69e7","slug":"definition","fullItemName":"Definition"},{"id":"1acc891f-d52d-5d63-b205-89550f729c09","slug":"causes","fullItemName":"Causes"},{"id":"40d3be43-feb4-5306-a60d-ec9e03885f7e","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"3ba3f93f-4120-52d3-8990-96f8e2d61822","slug":"prevalence","fullItemName":"Prevalence"},{"id":"907ee9c4-b3e5-548d-8cbf-755844108659","slug":"complications","fullItemName":"Complications"},{"id":"14e2ca0e-e787-59af-981b-fb20ca549650","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"1fd59997-277d-59b7-bff1-1b12b1d61e8c","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"74177232-92f1-5682-b32c-bf4738afe98c","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"9a71efb6-7a24-5578-a0ef-15e61d25dada","slug":"assessment","fullItemName":"Assessment"},{"id":"002ae3bb-5162-544f-aae0-ae958c081258","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"a66c4c3d-a19e-5402-865d-967da08018fe","fullItemName":"Management","slug":"management","subChapters":[{"id":"f7fa206c-b133-50b3-9ba2-1e1541a5f88c","slug":"acute-management-of-febrile-seizure","fullItemName":"Scenario: Acute management of febrile seizure"},{"id":"a24c98d4-0220-55ec-bd53-c090dc004fb2","slug":"management-after-a-febrile-seizure","fullItemName":"Scenario: Management after a febrile seizure"}]},{"id":"1b0a457d-3870-50be-aa29-42e89786e4e0","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"127470b6-a83f-58f7-925d-ea508c20c4f3","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0a0dc4aa-ec07-5bfa-9f2d-23a32419d47a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7cb62b99-ad2d-5782-a60e-479f261915a6","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"eb5ff0c3-e582-550c-9674-f587adc32240","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"38109d07-46c3-5d58-b12c-faa82e469115","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d89fa93b-1b1f-5964-b533-591ffb649835","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"191d5536-2674-5a42-9da0-8d0038438897","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"8b31df9d-3e48-548c-9547-2e93ba970361","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"686d7fb2-6952-5ec9-9f50-75af9ef53266","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field df101f53-f5ee-45e2-92c9-aca42a7a752a --><h3>Previous changes</h3><!-- end field df101f53-f5ee-45e2-92c9-aca42a7a752a -->","summary":null,"htmlStringContent":"<!-- begin item d8ba04c0-5d11-47cc-bad2-998adc52cf8b --><!-- begin field aca54bce-4024-4def-8fc8-868611eb1e68 --><p><strong>October 2013 </strong>— revised. A literature search was conducted in July 2013 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. Minor changes have been made to the National Institute for Health and Care Excellence's (NICE) 'traffic light' system, and the evidence-base has been updated to reflect this.</p><p><strong>July 2011 </strong>— minor update. More precise paracetamol dosing for children has been introduced by the Medicines and Healthcare products Regulatory Agency (MHRA). Prescriptions have been updated to reflect this revised dosing. Issued in July 2011.</p><p><strong>March 2011 </strong>— topic structure revised to ensure consistency across CKS topics. No changes to clinical recommendations have been made.</p><p><strong>September 2008 </strong>— minor typographical corrections to the <em>Search strategy </em>section. Issued in September 2008.</p><p><strong>February to June 2008 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. The title of the topic has changed from <em>Febrile convulsion </em>to <em>Febrile seizure </em>to reflect current terminology. A section on managing a child who is still having a seizure has been added.</p><p><strong>October 2006 </strong>— minor update. Antipyretic prescriptions updated in line with new doses of ibuprofen for children recommend by the British National Formulary (BNF). Issued in October 2006.</p><p><strong>October 2005 </strong>— minor technical update. Issued in November 2005.</p><p><strong>January 2005 </strong>— reviewed. Validated in March 2005 and issued in April 2005.</p><p><strong>September 2004 </strong>— minor technical update. Issued in September 2004.</p><p><strong>July 2001 </strong>— reviewed. Validated in November 2001 and issued in April 2002.</p><p><strong>October 1998 </strong>— written.</p><!-- end field aca54bce-4024-4def-8fc8-868611eb1e68 --><!-- end item d8ba04c0-5d11-47cc-bad2-998adc52cf8b -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}